Recurrent Melanoma Completed Phase 3 Trials for Fotemustine (DB04106)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01359956Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant MelanomaTreatment